EUVIMEDEUVIMED entdecken
Editorial

The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time

Vishisht Mehta

CHEST · 2026-04 · 169 (4) · 878-879

DOI: 10.1016/j.chest.2025.12.050 ↗

Kurz gefasst

Editorial in der Zeitschrift CHEST, 2026-04. Verfasst von Vishisht Mehta. Beteiligte Einrichtung: Comprehensive Cancer Centers of Nevada and the Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV. Electronic address: …. Die Arbeit nennt 9 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Comprehensive Cancer Centers of Nevada and the Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV. Electronic address: vishisht.mehta@gmail.com.

Zitieren

APA

Mehta, V. (2026). The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time. CHEST, 169(4), 878-879. https://doi.org/10.1016/j.chest.2025.12.050

Vancouver

Mehta V. The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time. CHEST. 2026;169(4):878-879. doi:10.1016/j.chest.2025.12.050

BibTeX
@article{Mehta2026,
  author = {Mehta, Vishisht},
  title = {The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time},
  journal = {CHEST},
  year = {2026},
  volume = {169},
  number = {4},
  pages = {878--879},
  doi = {10.1016/j.chest.2025.12.050}
}
Kostenlos starten →